RUSH UNIVERSITY MEDICAL CENTER

Nighttime light pollution linked to higher Alzheimer's risk, especially in those under 65, according to a study in *Frontiers in Neuroscience*. Lead researcher Robin Voigt-Zuwala suggests limiting night exposure to bright lights, such as using blackout curtains or eye masks, to mitigate risk.

IntraBio's NDA for IB1001, a treatment for Niemann-Pick Disease Type C, has been accepted by the FDA with a PDUFA date of September 24, 2024. IB1001 showed improvement in neurological signs, functioning, and quality of life in Phase 3 and IIb trials. IntraBio raised $40 million to support IB1001's commercialization.